NUVL Long Put Strategy
NUVL (Nuvalent, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL (Nuvalent, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $7.74B, a beta of 1.15 versus the broader market, a 52-week range of 68.64-113.015, average daily share volume of 567K, a public-listing history dating back to 2021, approximately 162 full-time employees. These structural characteristics shape how NUVL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.15 places NUVL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long put on NUVL?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current NUVL snapshot
As of May 15, 2026, spot at $102.64, ATM IV 47.30%, IV rank 25.41%, expected move 13.56%. The long put on NUVL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long put structure on NUVL specifically: NUVL IV at 47.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a NUVL long put, with a market-implied 1-standard-deviation move of approximately 13.56% (roughly $13.92 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NUVL expiries trade a higher absolute premium for lower per-day decay. Position sizing on NUVL should anchor to the underlying notional of $102.64 per share and to the trader's directional view on NUVL stock.
NUVL long put setup
The NUVL long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NUVL near $102.64, the first option leg uses a $105.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NUVL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NUVL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $105.00 | $7.25 |
NUVL long put risk and reward
- Net Premium / Debit
- -$725.00
- Max Profit (per contract)
- $9,774.00
- Max Loss (per contract)
- -$725.00
- Breakeven(s)
- $97.75
- Risk / Reward Ratio
- 13.481
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
NUVL long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on NUVL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$9,774.00 |
| $22.70 | -77.9% | +$7,504.68 |
| $45.40 | -55.8% | +$5,235.37 |
| $68.09 | -33.7% | +$2,966.05 |
| $90.78 | -11.6% | +$696.73 |
| $113.48 | +10.6% | -$725.00 |
| $136.17 | +32.7% | -$725.00 |
| $158.86 | +54.8% | -$725.00 |
| $181.56 | +76.9% | -$725.00 |
| $204.25 | +99.0% | -$725.00 |
When traders use long put on NUVL
Long puts on NUVL hedge an existing long NUVL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying NUVL exposure being hedged.
NUVL thesis for this long put
The market-implied 1-standard-deviation range for NUVL extends from approximately $88.72 on the downside to $116.56 on the upside. A NUVL long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long NUVL position with one put per 100 shares held. Current NUVL IV rank near 25.41% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NUVL at 47.30%. As a Healthcare name, NUVL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NUVL-specific events.
NUVL long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NUVL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NUVL alongside the broader basket even when NUVL-specific fundamentals are unchanged. Long-premium structures like a long put on NUVL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NUVL chain quotes before placing a trade.
Frequently asked questions
- What is a long put on NUVL?
- A long put on NUVL is the long put strategy applied to NUVL (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With NUVL stock trading near $102.64, the strikes shown on this page are snapped to the nearest listed NUVL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NUVL long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the NUVL long put priced from the end-of-day chain at a 30-day expiry (ATM IV 47.30%), the computed maximum profit is $9,774.00 per contract and the computed maximum loss is -$725.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NUVL long put?
- The breakeven for the NUVL long put priced on this page is roughly $97.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NUVL market-implied 1-standard-deviation expected move is approximately 13.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on NUVL?
- Long puts on NUVL hedge an existing long NUVL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying NUVL exposure being hedged.
- How does current NUVL implied volatility affect this long put?
- NUVL ATM IV is at 47.30% with IV rank near 25.41%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.